Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013-2021
{{output}}
Previous research shows that the benefits of phase-I oncology trials increased from 5 to 18% between 2000 and 2019 globally. However, the risk-benefit profile of phase-I trials in China is unclear. This study aims to analyze the risk-benefit profile of phase-I... ...